Company Description
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research.
The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.
Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services.
In addition, the company offers Olink normalized protein expression (NPX) data processing software, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics.
It sells its products and services through its own direct sales force in Sweden, the United States, rest of the Americas, rest of Europe, the Middle East, Africa, Japan, and internationally.
The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021.
Olink Holding AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
| Country | Sweden |
| Founded | 2004 |
| IPO Date | Mar 25, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 707 |
| CEO | Jon Heimer |
Contact Details
Address: Uppsala Science Park Uppsala, V7 SE-751 83 Sweden | |
| Phone | 46 (0) 18 444 39 70 |
| Website | olink.com |
Stock Details
| Ticker Symbol | OLK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001835539 |
| CUSIP Number | 680710100 |
| ISIN Number | US6807101000 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Jon Heimer | Chief Executive Officer and Director |
| Carl Raimond | Interim Chief Commercial Officer and President |
| Oskar Hjelm | Chief Financial Officer |
| Anna Marsell | Chief Operating Officer |
| Jan Medina CFA | Vice President of Investor Relations and Capital Markets |
| Linda Ramirez-Eaves Esq. | General Counsel |
| Andrea Prander | Corporate Communications Manager |
| Elias Berglund | Chief People Officer |
| Rickard El Tarzi | Chief Strategy and Product Officer |
| Maria Liminga Bjork | Chief Research and Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | SC TO-T/A | Filing |
| May 13, 2024 | 6-K | Report of foreign issuer |
| May 1, 2024 | SC 14D9/A | Filing |
| May 1, 2024 | SC TO-T/A | Filing |
| Apr 24, 2024 | SC TO-T/A | Filing |
| Apr 19, 2024 | 6-K | Report of foreign issuer |
| Apr 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 25, 2024 | 6-K | Report of foreign issuer |
| Mar 15, 2024 | 6-K | Report of foreign issuer |